<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2019//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_190101.dtd">
<PubmedArticleSet>
  <PubmedArticle>
    <MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM">
      <PMID Version="1">31198545</PMID>
      <DateRevised>
        <Year>2020</Year>
        <Month>09</Month>
        <Day>29</Day>
      </DateRevised>
      <Article PubModel="Electronic-eCollection">
        <Journal>
          <ISSN IssnType="Print">2048-8505</ISSN>
          <JournalIssue CitedMedium="Print">
            <Volume>12</Volume>
            <Issue>3</Issue>
            <PubDate>
              <Year>2019</Year>
              <Month>Jun</Month>
            </PubDate>
          </JournalIssue>
          <Title>Clinical kidney journal</Title>
          <ISOAbbreviation>Clin Kidney J</ISOAbbreviation>
        </Journal>
        <ArticleTitle>Are oxyphil cells responsible for the ineffectiveness of cinacalcet hydrochloride in haemodialysis patients?</ArticleTitle>
        <Pagination>
          <StartPage>433</StartPage>
          <EndPage>436</EndPage>
          <MedlinePgn>433-436</MedlinePgn>
        </Pagination>
        <ELocationID EIdType="doi" ValidYN="Y">10.1093/ckj/sfy062</ELocationID>
        <Abstract>
          <AbstractText>Parathyroid glands consist primarily of chief cells. In some cases, the proportion of parathyroid oxyphil cells increases in patients with chronic kidney disease. We describe a case of secondary hyperparathyroidism (SHPT) in a patient treated with haemodialysis who initially received large doses of vitamin D and calcium (Ca) supplements, as well as high doses of cinacalcet hydrochloride (C-HCl), but without any effect on parathyroid hormone levels. Following a successful parathyroidectomy, histopathological examination revealed that two of the parathyroid glands consisted of 40% of oxyphil cells. Oxyphil cells have significantly more Ca-sensing receptors (CaSRs) than chief cells, suggesting that CaSRs are involved in the transdifferentiation of chief cells to oxyphil cells. C-HCl treatment leads to a significant increase in parathyroid oxyphil cell content. This case suggests that C-HCl may induce specific phenotypic alterations in hyperplastic parathyroid glands in patients with severe SHPT.</AbstractText>
        </Abstract>
        <AuthorList CompleteYN="Y">
          <Author ValidYN="Y">
            <LastName>Rottembourg</LastName>
            <ForeName>Jacques</ForeName>
            <Initials>J</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Nephrology, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
          <Author ValidYN="Y">
            <LastName>Menegaux</LastName>
            <ForeName>Fabrice</ForeName>
            <Initials>F</Initials>
            <AffiliationInfo>
              <Affiliation>Department of Endocrine Surgery, Groupe Hospitalier Pitié-Salpêtrière, Paris, France.</Affiliation>
            </AffiliationInfo>
          </Author>
        </AuthorList>
        <Language>eng</Language>
        <PublicationTypeList>
          <PublicationType UI="D016428">Journal Article</PublicationType>
        </PublicationTypeList>
        <ArticleDate DateType="Electronic">
          <Year>2018</Year>
          <Month>07</Month>
          <Day>23</Day>
        </ArticleDate>
      </Article>
      <MedlineJournalInfo>
        <MedlineTA>Clin Kidney J</MedlineTA>
        <NlmUniqueID>101579321</NlmUniqueID>
        <ISSNLinking>2048-8505</ISSNLinking>
      </MedlineJournalInfo>
      <KeywordList Owner="NOTNLM">
        <Keyword MajorTopicYN="N">calcimimetic</Keyword>
        <Keyword MajorTopicYN="N">calcium-sensing receptor</Keyword>
        <Keyword MajorTopicYN="N">chronic kidney disease</Keyword>
        <Keyword MajorTopicYN="N">haemodialysis</Keyword>
        <Keyword MajorTopicYN="N">secondary hyperparathyroidism</Keyword>
      </KeywordList>
    </MedlineCitation>
    <PubmedData>
      <History>
        <PubMedPubDate PubStatus="received">
          <Year>2018</Year>
          <Month>2</Month>
          <Day>24</Day>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="entrez">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="pubmed">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>0</Minute>
        </PubMedPubDate>
        <PubMedPubDate PubStatus="medline">
          <Year>2019</Year>
          <Month>6</Month>
          <Day>15</Day>
          <Hour>6</Hour>
          <Minute>1</Minute>
        </PubMedPubDate>
      </History>
      <PublicationStatus>epublish</PublicationStatus>
      <ArticleIdList>
        <ArticleId IdType="pubmed">31198545</ArticleId>
        <ArticleId IdType="pmc">PMC6543953</ArticleId>
        <ArticleId IdType="doi">10.1093/ckj/sfy062</ArticleId>
        <ArticleId IdType="pii">sfy062</ArticleId>
      </ArticleIdList>
      <ReferenceList>
        <Reference>
          <Citation>
Chertow GM, Plone M, Dillon MA. 
et al.
Hyperparathyroidism and dialysis vintage. Clin Nephrol 2000; 54: 295–300</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">11076105</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42(4 Suppl 3): S1–S201</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">14520607</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ketteler M, Block GA, Evenepoel P. 
et al.
Executive summary of the 2017 KDIGO chronic kidney disease-mineral and bone disorder (CKD-MBD) guideline update: what’s changed and why it matters. Kidney Int 2017; 92: 26–36</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28646995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Urena P, Frazao JM.. 
Calcimimetic agents: review and perspectives. Kidney Int 2003; 63(Suppl 85): S91–S96</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12753275</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Urena P, Fouque D, Brunet P. 
et al.
Cinacalcet treatment for secondary hyperparathyroidism in dialysis patients in real-world clinical practice – the ECHO observational study: French experience. Nephrol Ther 2012; 8: 527–533</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23018042</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Komaba H, Nakanishi S, Fujimori A. 
et al.
Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment gland size in patients with secondary hyperparathyroidism. Clin J Am Soc Nephrol 2010; 5: 2305–2314</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2994093</ArticleId>
            <ArticleId IdType="pubmed">20798251</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Forni Ogna V, Pruijm M, Zweiacker C. 
et al.
Clinical benefits of an adherence monitoring program in the management of secondary hyperparathyroidism with cinacalcet: results of a prospective randomized controlled study. Bio Med Res Int 2013; 2013: 104892</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3732637</ArticleId>
            <ArticleId IdType="pubmed">23971019</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chertow GM, Block GA, Correa-Rotter R. 
et al.
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med 2012; 367: 2482–2494</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23121374</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wetmore JB, Gurevich K, Sprague S. 
et al.
A randomized trial of cinacalcet versus vitamin D analogs as monotherapy in secondary hyperparathyroidism (PARADIGM). Clin J Am Soc Nephrol 2015; 10: 1031–1040</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC4455208</ArticleId>
            <ArticleId IdType="pubmed">25904755</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Fishbane S, Shapiro WB, Corry DB. 
et al.
Cinacalcet-HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyroidism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin J Am Soc Nephrol 2008; 3: 1718–1725</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2572296</ArticleId>
            <ArticleId IdType="pubmed">18945995</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ketteler M, Martin KJ, Wolf M. 
et al.
Paracalcitol versus cinacalcet plus low-dose vitamin D therapy for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: results of the IMPACT SHPT study. Nephrol Dial Transplant 2012; 27: 3270–3278</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3408938</ArticleId>
            <ArticleId IdType="pubmed">22387567</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Messa P, Macario F, Yaqoob M. 
et al.
The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin J Am Soc Nephrol 2008; 3: 36–45</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2390975</ArticleId>
            <ArticleId IdType="pubmed">18178780</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Raggi P, Chertow GM, Torres PU. 
et al.
The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrol Dial Transplant 2011; 26: 1327–1339</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21148030</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Urena-Torres P, Bridges I, Christiano C. 
et al.
Efficacy of cinacalcet with low-dose vitamin D in incident haemodialysis subjects with secondary hyperparathyroidism. Nephrol Dial Transplant 2013; 28: 1241–1254</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">23328710</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Meola M, Petrucci I, Barsotti G.. 
Long-term treatment with Cinacalcet and conventional therapy reduces parathyroid hyperplasia in severe secondary hyperparathyroidism. Nephrol Dial Transplant 2009; 24: 982–989</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2644631</ArticleId>
            <ArticleId IdType="pubmed">19181759</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Chiu YW, Teitelbaum I, Misra M. 
et al.
Pill burden, adherence, hyperphosphatemia and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4: 1089–1096</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2689877</ArticleId>
            <ArticleId IdType="pubmed">19423571</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
de Francisco ALM, Gillespie IA, Gioni I. 
et al.
Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism. Nefrologia 2016; 36: 164–175</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">26654696</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Christie AC.
The parathyroid oxyphil cells. J Clin Pathol 1967; 20: 591–602</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC473518</ArticleId>
            <ArticleId IdType="pubmed">4880406</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ritter CS, Haughey BH, Miller B. 
et al.
Differential gene expression by oxyphil cells of human parathyroid glands. J Clin Endocrinol Metab 2012; 97: E1499–E1505</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC3591682</ArticleId>
            <ArticleId IdType="pubmed">22585091</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Lomonte C, Vernaglione L, Chimienti D. 
et al.
Does vitamin D receptor and calcium receptor activation therapy play a role in the histopathologic alterations of the parathyroid glands in refractory uremic hyperparthyroidism. Clin J Am Soc Nephrol 2008; 3: 794–799</Citation>
          <ArticleIdList>
            <ArticleId IdType="pmc">PMC2386693</ArticleId>
            <ArticleId IdType="pubmed">18322048</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ritter C, Miller B, Coyne DW. 
et al.
Paracalcitol and cinacalcet have disparate actions on parathyroid oxyphil cell content in patients with chronic kidney disease. Kidney Int 2017; 92: 1217–1222</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">28750928</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Ritter CS, Haughey BH, Armbrecht HJ. 
et al.
Distribution and regulation of the 25-hydroxyvitamin D3 1α-hydroxylase in human parathyroid glands. J Steroid Biochem Mol Biol 2012; 130: 73–80</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">22326730</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Sumida K, Nakamura M, Ubara Y. 
et al.
Histopathological alterations of the parathyroid glands in haemodialysis patients with secondary hyperparathyroidism refractory to cinacalcet hydrochloride. J Clin Pathol 2011; 64: 756–760</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">21565858</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Mizobuchi M, Ogata H, Hatamura I. 
et al.
Activation of calcium-sensing receptor accelerates apoptosis in hyperparathyroid cells. Biochem Biophys Res Commun 2007; 362: 11–16</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">17706605</ArticleId>
          </ArticleIdList>
        </Reference>
        <Reference>
          <Citation>
Wada M, Nagano N.. 
Control of parathyroid cell growth by calcimimetics. Nephrol Dial Transplant 2003; 18(Suppl 3): S13–S17</Citation>
          <ArticleIdList>
            <ArticleId IdType="pubmed">12771292</ArticleId>
          </ArticleIdList>
        </Reference>
      </ReferenceList>
    </PubmedData>
  </PubmedArticle>
</PubmedArticleSet>
